RA Capital backs mammoth $60m Series C round for RNA Interference


dnaRA Capital has helped emerging pharmaceutical company RNA Interference close an enormous $60m Series C financing round.

Brookside Capital, Deerfield and Omega Funds also took part in the oversubscribed fundraise, as well as all five of RNA’s existing investors.

They comprise Abingworth Management, Domain Associates, Oxford Bioscience Partners, Skyline Ventures and SR One.

RA Capital partner Peter Kolchinsky has joined Dicerna’s board of directors as part of the financing.

He said, “Dicerna has strong science and a capable management team that is generating an impressive pipeline of next generation RNAi therapeutics addressing serious unmet medical needs.

“The company’s novel approach to RNAi will allow it to develop therapeutics with greater potency and enhanced delivery potential, differentiating it from other RNAi approaches.

“I look forward to working closely with the board as the company transitions multiple preclinical programs into human clinical trials over the next 12 to 18 months.”

Copyright © 2013 AltAssets